Boston Scientific apologizes for embargo breach that got its Watchman trial pulled from conference

March 10, 2013 by Arezu Sarvestani

American College of Cardiology conference organizers cancel the highly anticipated presentation of preliminary results from Boston Scientific's PREVAIL study after the company accidentally leaks the data ahead of time. Boston Scientific publishes the slides that would have been presented at this weekend's American College of Cardiology meeting had the company preserved the embargo on the findings.

Updated March 9, 2013, at 8:30 p.m. PST with comment, slides from Boston Scientific.

American College of Cardiology conference 2013 logo

Medical device giant Boston Scientific (NYSE:BSX) did not present its highly anticipated PREVAIL clinical trial results at the American College of Cardiology conference as planned this weekend after the presentation was canceled when the company inadvertently leaked the data ahead of time.

Boston Scientific sent a press release to its investors Saturday morning, breaking an embargo on the study that was meant to be lifted during the presentation.

Sign up to get our free newsletters delivered right to your inbox.

The news is another dramatic turn for the PREVAIL results, which were at the center of controversy last week over the company's initial announcement that it would unveil only the acute procedural safety results from the trial, leaving out 2 co-primary endpoints.